Eli Lilly's retatrutide significantly reduces sleep apnea severity, knee osteoarthritis pain, and promotes substantial weight loss in adults with obesity, trial results reveal.
The findings were presented at a conference
Jun 07, 2026
01:57 pm
What's the storyEli Lilly, a leading pharmaceutical company, has announced promising results from clinical trials of its next-generation obesity drug, retatrutide.
The drug not only aids in weight loss but also alleviates sleep apnea and knee pain.
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
Eli Lilly’s new weight loss drug may also help sleep apnea according to Phase 3 data
Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
Lilly shares safety, tolerability data on its next-gen obesity drug
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Retatrutida: pesquisa mostra perda de até 28% do peso com nova caneta | G1
